ImmunityBio Inc. Common Stock vs Rubrik Inc. Class A Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.33B), while Rubrik Inc. Class A Common Stock trades at $121.41 (market cap $25.65B). The key difference: Rubrik Inc. Class A Common Stock is far larger — about 2.5× ImmunityBio Inc. Common Stock's market cap, and Rubrik Inc. Class A Common Stock is trading nearer its 52-week high, ImmunityBio Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Rubrik Inc. Class A Common Stock for 0 Days on average.
| IBRX | RBRK | |
|---|---|---|
Market Cap | $10.33B | $25.65B |
Volume | 11,745,198 | 2,354,939 |
Sector | Health | Technology |
52-Week High | $11.55 | $125.80 |
52-Week Low | $1.98 | $43.81 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.79B | $25.05B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →